These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 10378847)

  • 1. A survey of phlebotomy among persons with hemochromatosis.
    McDonnell SM; Grindon AJ; Preston BL; Barton JC; Edwards CQ; Adams PC
    Transfusion; 1999 Jun; 39(6):651-6. PubMed ID: 10378847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severity of iron overload in hemochromatosis: effect of volunteer blood donation before diagnosis.
    Barton JC; Preston BL; McDonnell SM; Rothenberg BE
    Transfusion; 2001 Jan; 41(1):123-9. PubMed ID: 11161257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemochromatosis subjects as allogeneic blood donors: a prospective study.
    Leitman SF; Browning JN; Yau YY; Mason G; Klein HG; Conry-Cantilena C; Bolan CD
    Transfusion; 2003 Nov; 43(11):1538-44. PubMed ID: 14617312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemochromatosis patients as voluntary blood donors.
    Power TE; Adams PC
    Can J Gastroenterol; 2004 Jun; 18(6):393-6. PubMed ID: 15190395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemochromatosis probands as blood donors.
    Barton JC; Grindon AJ; Barton NH; Bertoli LF
    Transfusion; 1999 Jun; 39(6):578-85. PubMed ID: 10378837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A survey of 2,851 patients with hemochromatosis: symptoms and response to treatment.
    McDonnell SM; Preston BL; Jewell SA; Barton JC; Edwards CQ; Adams PC; Yip R
    Am J Med; 1999 Jun; 106(6):619-24. PubMed ID: 10378618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of FDA variance for blood collection from individuals with hereditary hemochromatosis at a 398-bed hospital-based donor center.
    Gribble DM; Chaffin DJ; Bryant BJ
    Immunohematology; 2009; 25(4):170-3. PubMed ID: 20406025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient compliance with phlebotomy therapy for iron overload associated with hemochromatosis.
    Hicken BL; Tucker DC; Barton JC
    Am J Gastroenterol; 2003 Sep; 98(9):2072-7. PubMed ID: 14499790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythrocytapheresis versus phlebotomy in the initial treatment of HFE hemochromatosis patients: results from a randomized trial.
    Rombout-Sestrienkova E; Nieman FH; Essers BA; van Noord PA; Janssen MC; van Deursen CT; Bos LP; Rombout F; van den Braak R; de Leeuw PW; Koek GH
    Transfusion; 2012 Mar; 52(3):470-7. PubMed ID: 21848963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Native American ancestry on iron-related phenotypes of Alabama hemochromatosis probands with HFE C282Y homozygosity.
    Barton JC; Barton EH; Acton RT
    BMC Med Genet; 2006 Mar; 7():22. PubMed ID: 16533407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of hemochromatosis. Hemochromatosis Management Working Group.
    Barton JC; McDonnell SM; Adams PC; Brissot P; Powell LW; Edwards CQ; Cook JD; Kowdley KV
    Ann Intern Med; 1998 Dec; 129(11):932-9. PubMed ID: 9867745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence, donation practices, and risk assessment of blood donors with hemochromatosis.
    Sanchez AM; Schreiber GB; Bethel J; McCurdy PR; Glynn SA; Williams AE; Gilcher R;
    JAMA; 2001 Sep; 286(12):1475-81. PubMed ID: 11572740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reassessing the safety concerns of utilizing blood donations from patients with hemochromatosis.
    Winters AC; Tremblay D; Arinsburg S; Mascarenhas J; Schiano TD
    Hepatology; 2018 Mar; 67(3):1150-1157. PubMed ID: 28902419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficiency of therapeutic erythrocytapheresis compared to phlebotomy: a mathematical tool for predicting response in hereditary hemochromatosis, polycythemia vera, and secondary erythrocytosis.
    Evers D; Kerkhoffs JL; Van Egmond L; Schipperus MR; Wijermans PW
    J Clin Apher; 2014 Jun; 29(3):133-8. PubMed ID: 24130064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron deficiency due to excessive therapeutic phlebotomy in hemochromatosis.
    Barton JC; Bottomley SS
    Am J Hematol; 2000 Nov; 65(3):223-6. PubMed ID: 11074539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hereditary hemochromatosis: missed diagnosis or misdiagnosis?
    Cherfane CE; Hollenbeck RD; Go J; Brown KE
    Am J Med; 2013 Nov; 126(11):1010-5. PubMed ID: 24054178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MCV as a guide to phlebotomy therapy for hemochromatosis.
    Bolan CD; Conry-Cantilena C; Mason G; Rouault TA; Leitman SF
    Transfusion; 2001 Jun; 41(6):819-27. PubMed ID: 11399827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic phlebotomy procedures and their impact on a rural hospital's red blood cell inventory and fiscal stature.
    Flynn RC; Bryant BJ
    Transfusion; 2011 Dec; 51(12 Pt 2):2761-6. PubMed ID: 22150687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phlebotomy-mobilized iron as a surrogate for liver iron content in hemochromatosis patients.
    Phatak PD; Barton JC
    Hematology; 2003 Dec; 8(6):429-32. PubMed ID: 14668040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phlebotomy, blood donation, and hereditary hemochromatosis.
    Conry-Cantilena C
    Transfus Med Rev; 2001 Apr; 15(2):136-43. PubMed ID: 11309733
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.